Evidence used
- No CISA KEV confirmation is currently recorded.
- A structured source references public exploit or proof-of-concept material.
- EPSS is 87.72% for the current model date.
BlackTreeCVE IntelligenceUnknown · Unknown
High technical severity with public exploit material referenced by a structured source; prioritise exposed affected systems while verifying vendor guidance.
High technical severity with public exploit material referenced by a structured source; prioritise exposed affected systems while verifying vendor guidance.
Fix not verifiedThe Intel LANDesk Common Base Agent (CBA) in Symantec Alert Management System 2 (AMS2), as used in Symantec System Center (SSS); Symantec AntiVirus Server; Symantec AntiVirus Central Quarantine Server; Symantec AntiVirus (SAV) Corporate Edition 9 before 9.0 MR7, 10.0 and 10.1 before 10.1 MR8, and 10.2 before 10.2 MR2; Symantec Client Security (SCS) 2 before 2.0 MR7 and 3 before 3.1 MR8; and Symantec Endpoint Protection (SEP) before 11.0 MR3, allows remote attackers to execute arbitrary commands via a crafted packet whose contents are interpreted as a command to be launched in a new process by the CreateProcessA function.
The Intel LANDesk Common Base Agent (CBA) in Symantec Alert Management System 2 (AMS2), as used in Symantec System Center (SSS); Symantec AntiVirus Server; Symantec AntiVirus Central Quarantine Server; Symantec AntiVirus (SAV) Corporate Edition 9 before 9.0 MR7, 10.0 and 10.1 before 10.1 MR8, and 10.2 before 10.2 MR2; Symantec Client Security (SCS) 2 before 2.0 MR7 and 3 before 3.1 MR8; and Symantec Endpoint Protection (SEP) before 11.0 MR3, allows remote attackers to execute arbitrary commands via a crafted packet whose contents are interpreted as a command to be launched in a new process by the CreateProcessA function.
Untrusted data can cross into a code-evaluation path and be interpreted as executable instructions.
An attacker operating through the affected interface may attempt exploitation when the stated preconditions are met. If successful, the issue may execute code or commands in the affected security context.
The Intel LANDesk Common Base Agent (CBA) in Symantec Alert Management System 2 (AMS2), as used in Symantec System Center (SSS); Symantec AntiVirus Server; Symantec AntiVirus Central Quarantine Server; Symantec AntiVirus (SAV) Corporate Edition 9 before 9.0 MR7, 10.0 and 10.1 before 10.1 MR8, and 10.2 before 10.2 MR2; Symantec Client Security (SCS) 2 before 2.0 MR7 and 3 before 3.1 MR8; and Symantec Endpoint Protection (SEP) before 11.0 MR3, allows remote attackers to execute arbitrary commands via a crafted packet whose contents are interpreted as a command to be launched in a new process by the CreateProcessA function.
Untrusted data can cross into a code-evaluation path and be interpreted as executable instructions.
An attacker operating through the affected interface may attempt exploitation when the stated preconditions are met. If successful, the issue may execute code or commands in the affected security context.
CVSS severity, EPSS forecast probability, public exploit material and CISA-confirmed exploitation are separate signals.
No CISA KEV match was present at the last successful refresh. This means no confirmation from that source, not proof of no exploitation.
A structured CVE source labels at least one public reference as exploit material. BlackTree has not independently validated that it is safe, reliable or weaponised.
CWE-94: Improper Control of Generation of Code ('Code Injection'). The product constructs all or part of a code segment using externally-influenced input from an upstream component, but it does not neutralize or incorrectly neutralizes special elements that could modify the syntax or behavior of the intended code segment.
AV:N/AC:L/Au:N/C:C/I:C/A:COperational remediation based on structured source evidence.
Published 29 Apr 2009 · Last source change 7 Aug 2024, 05:13 UTC · CWE-94 · Improper Control of Generation of Code ('Code Injection')
Missing structured fields: affected product. Missing data is not evidence of low risk; review the primary advisory.